SCHEMBL1760897

SCHEMBL1760897

COc1ncnc2sc(NC(=O)N3CCC(Cc4ccc(C(F)(F)F)cc4)C3)nc12

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 7/20 0.41
ADORA1 P30542 7/20 0.41
ADORA2B P29275 5/20 0.41
CCR3 P51677 3/20 0.41
FAAH O00519 2/20 0.39
HIF1A Q16665 1/20 0.39
EPAS1 Q99814 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SLC2A1 P11166 1/20 0.39
CCR5 P51681 1/20 0.38
RPS6KB1 P23443 1/20 0.38
TRPV1 Q8NER1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1760975 0.89 CCR3 (0.41) ADORA2AADORA1CCR3FAAHMEN1
SCHEMBL1760986 0.89 MEN1 (0.50) CCR3FAAHMEN1KMT2ASMN1; SMN2
SCHEMBL2931791 0.87 RPS6KB1 (0.37) ADORA2AADORA1ADORA2BCCR3HIF1A
SCHEMBL1761011 0.87 CCR3 (0.46) ADORA2AADORA1CCR3MEN1KMT2A
SCHEMBL1760886 0.86 ADORA2B (0.51) ADORA2AADORA1ADORA2BCCR3FAAH
SCHEMBL1761027 0.86 ADORA2B (0.46) ADORA2AADORA1ADORA2BCCR3FAAH
SCHEMBL1760846 0.81 PDE10A (0.44) ADORA2AADORA1ADORA2BTRPV1
SCHEMBL12592858 0.78 ADORA2B (0.51) ADORA2AADORA1ADORA2B
SCHEMBL1761037 0.78 ADORA2A (0.61) ADORA2AADORA1ADORA2BMEN1KMT2A
SCHEMBL1760963 0.78 ADORA2A (0.42) ADORA2AADORA1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947692-B2 Substituted thiazolo[5,4-d]pyrimidine urea derivatives HOFFMANN-LA ROCHE INC. (US) 2011-05-24 US claimed
US-7947692-B2 Substituted thiazolo[5,4-d]pyrimidine urea derivatives HOFFMANN-LA ROCHE INC. (US) 2011-05-24 US disclosed
US-7947692-B2 Substituted thiazolo[5,4-d]pyrimidine urea derivatives HOFFMANN-LA ROCHE INC. (US) 2011-05-24 US disclosed
US-7947692-B2 Substituted thiazolo[5,4-d]pyrimidine urea derivatives HOFFMANN-LA ROCHE INC. (US) 2011-05-24 US disclosed
WO-2007134958-A1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-29 WO disclosed
US-20070270433-A1 Thiazolo-pyrimidine/pyridine urea derivatives BRINKMAN JOHN A 2007-11-22 US disclosed
US-20070270433-A1 Thiazolo-pyrimidine/pyridine urea derivatives BRINKMAN JOHN A 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270433-A1 Thiazolo-pyrimidine/pyridine urea derivatives ADORA2B, UTS2R, TBXA2R ADORA2A 4/4885ADORA1 5/4885ADORA2B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.